aTyr Pharma, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 08 Jun 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 05 Dec 2025 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →aTyr Pharma, Inc. — Overview & Financial Snapshot
aTyr Pharma, Inc. (NasdaqCM: ATYR) is a Healthcare company, ranked #2,904 of 6,774 companies globally and #1,085 of 4,000 in United States on PositoAI, with a Positivity Score of 21,043. Its market capitalisation is ₹157.40 Cr ($16.67M), P/E ratio is -0.3 and P/B ratio is 0.34. It currently has 2 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →